Roconkibart

偌考奇拜单抗

Report date: 2025/12/08 10:16:40

Base Information

Drug NameRoconkibart
Drug Alias Name重组人源化抗IL-17A单克隆抗体JS005
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionInterleukin 17A inhibitors
TargetsInterleukin 17A
Therapy Area/IndicationsPlaque psoriasisNon-radiographic axial spondyloarthritisPalmoplantar pustulosis +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusNDA/BLA
Highest Status in ChinaNDA/BLA
Originator CompaniesShanghai Junshi Biosciences Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesSuzhou Union Biopharm Biosciences Co LtdShanghai Junshi Biosciences Co LtdShanghai Junshi Biological Engineering Co Ltd +[4] 
Inactive CompaniesN/A
Active IndicationsPlaque psoriasisPalmoplantar pustulosisSpondylitis, Ankylosing +[4] 
Inactive IndicationsNon-radiographic axial spondyloarthritis

Other Information

ATC CodeN/A
Related LinksN/A